Volume 7.12 | Mar 29

Hematopoiesis News 7.12 March 29, 2016
Hematopoiesis News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  HN on Twitter
DNMT3A R882 Mutants Interact with Polycomb Proteins to Block Hematopoietic Stem and Leukemic Cell Differentiation
Investigators showed that, in murine transplantation experiments, recipients transplanted with DNMT3A mutant-transduced cells exhibit aberrant hematopoietic stem cell accumulation. [Nat Commun] Full Article
Learn more about new StemSpan™ Erythroid Expansion Medium. Combine with Erythroid Expansion Supplement to generate 1000s of erythroid cells per input human CD34+ cell in ACF conditions.
PUBLICATIONS (Ranked by impact factor of the journal)
Single-Cell RNA Sequencing Reveals Molecular and Functional Platelet Bias of Aged Hematopoietic Stem Cells
By analyzing hematopoietic stem cell (HSC) transcriptomes and HSC function at the single-cell level, scientists identified increased molecular platelet priming and functional platelet bias as the predominant age-dependent change to HSCs, including a significant increase in a previously unrecognized class of HSCs that exclusively produce platelets. [Nat Commun] Full Article

MIP-1α/CCL3-Expressing Basophil-Lineage Cells Drive the Leukemic Hematopoiesis of Chronic Myeloid Leukemia in Mice
To delineate the cellular process facilitating CCL3-mediated crosstalk between normal and leukemic hematopoiesis, investigators precisely examined CCL3-expressing cells and their functions in both normal hematopoiesis and chronic myeloid leukemia leukemogenesis. [Blood] Abstract

Leukemic Stem Cell Quantification in Newly Diagnosed Chronic Myeloid Leukemia Patients Predicts Response to Nilotinib Therapy
Researchers identified Philadelphia chromosome positive CD34+CD38 bone marrow cells and addressed their response-predictive value in chronic myeloid leukemia patients subjected to nilotinib. [Clin Cancer Res] Abstract

MiR144/451 Expression Is Repressed by RUNX1 during Megakaryopoiesis and Disturbed by RUNX1/ETO
Investigators found that the hematopoietic master regulator RUNX1 controls the expression of certain microRNAs, of importance during erythroid/megakaryocytic differentiation. [PLoS Genet] Full Article

Abnormal Proplatelet Formation and Emperipolesis in Cultured Human Megakaryocytes from Gray Platelet Syndrome Patients
Researchers report the first analysis of cultured megakaryocytes from Gray Platelet Syndrome patients with NBEAL2 mutations. Megakaryocytes cultured from peripheral blood or bone marrow hematopoietic progenitor cells from four patients were used to investigate megakaryopoiesis, megakaryocyte morphology and platelet formation. [Sci Rep] Full Article

Long-Term Restoration of Thymidine Phosphorylase Function and Nucleoside Homeostasis Using Hematopoietic Gene Therapy in a Murine Model of MNGIE
Scientists showed that ectopic expression of thymidine phosphroylase in the hematopoietic system restores normal nucleoside levels in plasma, as well as in tissues affected in mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) such as small intestine, skeletal muscle, brain and liver. [Hum Gene Ther] Abstract

GATA-1 Inhibits PU.1 Gene via DNA and Histone H3K9 Methylation of Its Distal Enhancer in Erythroleukemia
Researchers present evidence that GATA-1 binds to the PU.1 gene and inhibits its expression in human acute myeloid leukemia-erythroleukemias. [PLoS One] Full Article


Long-Term Follow-Up of Patients with Acute Myeloid Leukemia Surviving and Free of Disease Recurrence for At Least 2 Years after Autologous Stem Cell Transplantation: A Report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Leukemia recurrence is a major cause of treatment failure after autologous stem cell transplantation for acute myeloid leukemia. It usually occurs within the first 2 years after transplantation. Researchers assessed the follow-up of and characterize risk factors for outcome among patients who survived free of disease recurrence after this period. [Cancer] Abstract

Somatic, Hematologic Phenotype, Long-Term Outcome and Effect of Hematopoietic Stem Cell Transplantation. An Analysis of 97 Fanconi Anemia Patients from the Italian National Database on Behalf of the Marrow Failure Study Group of the AIEOP (Italian Association of Pediatric Hematology-Oncology)
Scientists analyzed 97 Fanconi Anemia patients from a clinic/biological database for genotype, somatic and hematologic phenotype, adverse hematological events, solid tumors and treatment. [Am J Hematol] Abstract

SmartDish™ with STEMgrid™-6 for Accurate Counting of Hematopoietic CFU Assays
Caught in a Wnt Storm: Complexities of Wnt Signaling in Hematopoiesis
The Wnt pathway in recent years has been studied by various research groups working on hematopoietic stem cells, resulting in rather contradicting conclusions. The authors discuss and interpret the results of these studies and propose that Wnt dosage, the source of HSCs and interactions with other pathways explain these disparate results. [Exp Hematol] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.
Ligand Partner Spectrum Pharmaceuticals Receives FDA Approval of EVOMELA™ (Melphalan) for Injection
Ligand Pharmaceuticals Incorporated announced that Spectrum Pharmaceuticals, Inc. received approval from the U.S. Food and Drug Administration (FDA) of EVOMELA™ for use in two indications: 1) as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with MM, and 2) for the palliative treatment of patients with MM for whom oral therapy is not appropriate. [Ligand Pharmaceuticals Incorporated] Press Release

Children’s Hospital Los Angeles to Initiate Clinical Trial for Kids with Treatment-Resistant Leukemia
The Children’s Center for Cancer and Blood Diseases at Children’s Hospital Los Angeles is one of the first sites in the world to offer a promising new investigational therapy to treat pediatric acute lymphoblastic leukemia. [Children’s Hospital Los Angeles] Press Release

From our sponsor: Working with blood? Download the immune cell frequencies app.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW World Cord Blood Europe
May 18-19, 2016
London, United Kingdom

Visit our events page to see a complete list of events in the hematopoiesis community.
NEW Postdoctoral Scientist – Hematological Malignancies (Max Delbruck Center for Molecular Medicine in the Helmholtz Association)

Scientist – Hematology (STEMCELL Technologies Inc.)

Postdoctoral Fellow – Molecular and Cellular Basis of Hematopoiesis (University of Cincinnati)

Postdoctoral Research Associate – Blood Stem cell Microenvironment (University of Illinois)

Associate Scientist – Hematopoietic Stem Cell Biology (Editas Medicine)

Research Associate – Hematopoietic Stem Cell Biology (Editas Medicine)

Postdoctoral Fellow Positions – Leukemogenesis (The University of Alabama)

Postdoctoral Fellow – Hematology/Oncology (Boston Children’s Hospital)

Postdoctoral Fellow – Cancer Stem Cell Biology (McGill University Health Center)

Postdoctoral Fellow – Cancer Biology (National University of Singapore)

PhD Position – Leukemogenesis and Treatment Resistance (Institute for Tumor Biology and Experimental Therapy)

Assistant/Associate/Full Member Faculty – Myeloid Malignancies (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Hematopoiesis News: Archives | Events | Contact Us